Your browser doesn't support javascript.
loading
Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer.
Goldman, Jonathan W; Sholl, Lynette M; Dacic, Sanja; Fishbein, Michael C; Murciano-Goroff, Yonina R; Rajaram, Ravi; Szymczak, Sylwia; Szpurka, Anna M; Chao, Bo H; Drilon, Alexander.
Affiliation
  • Goldman JW; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
  • Sholl LM; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
  • Dacic S; Department of Pathology, Yale School of Medicine, New Haven, CT, United States.
  • Fishbein MC; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
  • Murciano-Goroff YR; Department of Medicine, Memorial Sloan-Kettering Cancer Center New York, NY, United States.
  • Rajaram R; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Szymczak S; Loxo@Lilly, Eli Lilly and Company, Warsaw, Poland.
  • Szpurka AM; Loxo@Lilly, Eli Lilly and Company, Indianapolis, IN, United States.
  • Chao BH; Loxo@Lilly, Eli Lilly and Company, New York, NY, United States.
  • Drilon A; Department of Medicine, Memorial Sloan-Kettering Cancer Center New York, NY, United States.
Front Oncol ; 13: 1178313, 2023.
Article in En | MEDLINE | ID: mdl-37274265

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: Front Oncol Year: 2023 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: Front Oncol Year: 2023 Document type: Article Affiliation country: Country of publication: